CareDx Inc
NASDAQ:CDNA

Watchlist Manager
CareDx Inc Logo
CareDx Inc
NASDAQ:CDNA
Watchlist
Price: 23.13 USD 2.44% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
CareDx Inc?
Write Note

CareDx Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CareDx Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
CareDx Inc
NASDAQ:CDNA
Pre-Tax Income
-$143.3m
CAGR 3-Years
-97%
CAGR 5-Years
-44%
CAGR 10-Years
-60%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

CareDx Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in South San Francisco, California and currently employs 633 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products include AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. The company develops and provides diagnostic surveillance testing services for various transplant recipients.

CDNA Intrinsic Value
16.9 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is CareDx Inc's Pre-Tax Income?
Pre-Tax Income
-143.3m USD

Based on the financial report for Sep 30, 2024, CareDx Inc's Pre-Tax Income amounts to -143.3m USD.

What is CareDx Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-60%

Over the last year, the Pre-Tax Income growth was -59%. The average annual Pre-Tax Income growth rates for CareDx Inc have been -97% over the past three years , -44% over the past five years , and -60% over the past ten years .

Back to Top